Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand
Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves Fayuvi
Pharmaceutical Executive Daily: FDA Approves New Indication for Kerendia
Pharmaceutical Executive Daily: Novo Partners with Anthropic
Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership
Get summaries like this every morning.
Free AI-powered recaps of Pharmaceutical Executive and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.